Study of the Immune Response in the Elderly: Is It Necessary to Develop a Vaccine against Neisseria meningitidis for the Aged?

Table 1

Meningococcal conjugate and protein vaccines currently licensed and their composition, age indication, and immunization schemes.

Vaccine	Pharma	Composition	Age group indicated	Immunization scheme	Reference
Menjugate®	GlaxoSmithKline (GSK)	Meningococcal C oligosaccharide conjugated with CRM197 + aluminum hydroxide	>2 months of age, teenagers, and adults	2–12 months: two doses with an interval of at least 2 months between the doses; >12 months, teenagers, and adults: a single dose	[46]
Menactra®	Sanofi Pasteur	Meningococcal A, C, Y, and W-135 polysaccharides conjugated with DT	9 months through 55 years of age	9–23 months: two doses with an interval of at least 3 months between the doses; 2–55 years: a single dose	[47]
MenAfriVac®	Serum Institute of India	Meningococcal A polysaccharide conjugated with TT + aluminum phosphate	1 year of age, adolescents, and adults up to 29 years of age	A single dose	[48]
Meningitec®	Pfizer	Meningococcal C oligosaccharide conjugated with CRM197 + aluminum phosphate	>6 weeks of age, adolescents, and adults	<12 months: three doses with an interval of at least 1 month between the doses; >12 months, adolescents, and adults: a single dose	[49]
Meninvact®	Sanofi Pasteur	Meningococcal C oligosaccharide conjugated with CRM197 + aluminum hydroxide	>2 months of age, teenagers, and adults	2–12 months: two doses with an interval of at least 2 months between the doses; >12 months, teenagers, and adults: a single dose	[50]
Menveo®	GlaxoSmithKline (GSK)	Meningococcal A, C, Y, and W-135 oligosaccharides conjugated with CRM197	>2 months through 55 years of age	2–6 months: four doses, administrated at 2, 4, 6, and 12 months of age; 7–23 months, nonvaccinated: two doses with an interval of at least 3 months between the doses; >2 years, teenagers, and adults through 55 years: a single dose	[51]
Neisvac-C®	Baxter	Meningococcal C polysaccharide conjugated with TT + aluminum hydroxide	>2 months and adults	2–12 months: two doses with an interval of at least 2 months between the doses; >12 months, teenagers, and adults: a single dose	[52]
Nimenrix®	Pfizer	Meningococcal A, C, Y, and W-135 polysaccharides conjugated with TT	>12 months and adults	A single dose	[53]
Bexsero®	GlaxoSmithKline (GSK)	NHBA + NadA + fHbp + OMVs from NZ98/254 + aluminum hydroxide	>2 months and adults	2–5 months: three doses with an interval not less than 1 month; booster dose between 12 and 15 months; 3-5 months: two doses with an interval of at least 2 months between the doses; booster dose between 12 and 15 months; 6–11 months: two doses with an interval of at least 2 months between the doses; booster dose in the second year of life; 12–23 months: two doses with an interval of at least 2 months between the doses; booster dose with an interval of 12 to 23 months between primary series; 2 years and adults: two doses with an interval of at least 1 month between the doses	[54]
Trumenba®	Wyeth Pharmaceuticals	fHbp + aluminum phosphate	10 to 25 years of age	Three-dose schedule: 0, 1–2, and 6 months; Two-dose schedule: 0 and 6 months	[55]

CRM197: Corynebacterium diphtheriae cross-reactive material 197; DT: diphtheria toxoid; fHbp: factor H binding protein; NadA: Neisseria adhesin A; NHBA: Neisserial heparin binding antigen; OMVs: outer membrane vesicles; TT: tetanus toxoid.